Compare NTRS & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRS | KVUE |
|---|---|---|
| Founded | 1889 | 2022 |
| Country | United States | United States |
| Employees | 23800 | N/A |
| Industry | Major Banks | Specialty Chemicals |
| Sector | Finance | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 33.7B |
| IPO Year | N/A | 2023 |
| Metric | NTRS | KVUE |
|---|---|---|
| Price | $160.47 | $17.63 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 11 |
| Target Price | ★ $163.55 | $19.45 |
| AVG Volume (30 Days) | 1.1M | ★ 14.9M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | 1.94% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $8.40 | $4.85 |
| Revenue Next Year | $4.13 | $2.63 |
| P/E Ratio | ★ $16.88 | $71.34 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $104.09 | $14.02 |
| 52 Week High | $173.19 | $24.60 |
| Indicator | NTRS | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 54.09 | 53.02 |
| Support Level | $135.49 | $17.20 |
| Resistance Level | $173.19 | $17.84 |
| Average True Range (ATR) | 4.38 | 0.33 |
| MACD | -1.25 | 0.04 |
| Stochastic Oscillator | 7.26 | 68.75 |
Northern Trust is a leading provider of wealth management, asset servicing, asset management, and banking to corporations, institutions, affluent families, and individuals. Founded in Chicago in 1889, Northern Trust has offices in 20 states and Washington, D.C. as well as 23 locations in Canada, Europe, the Middle East, and Asia-Pacific. As of December 2025, Northern Trust had assets under custody or administration of $18.7 trillion and assets under management of $1.8 trillion.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.